Conference
A cost-utility analysis of enfortumab vedotin and pembrolizumab versus nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma
Authors
Cheun D; Bernardino R; May J; Papasideris M; Bremner K; Fleshner N; Lalani AK; Ong M; Wong W; Wallis C
Volume
87
Publisher
ELSEVIER
Publication Date
March 1, 2025
Conference proceedings
EUROPEAN UROLOGY
ISSN
0302-2838